Trade Name Mepron
Orphan Indication Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3
USA Market Approval USA
USA Designation Date 1991-08-14 00:00:00
Sponsor Glaxo Wellcome Research and Development;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709